Biohaven pops the Alzheimer’s bubble
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Nantkwest tries to catch the NK cell wave
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
J&J provides early hope for single-dose Covid-19 vaccine
Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.
Lilly boosts biopharma with an early Alzheimer’s signal
Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.
Pivotal valrox data give Biomarin déjà vu
Waning factor VIII levels mean the durability question is still unanswered.
Sanofi makes a pre-JP Morgan splash with Kymab
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Gene therapy trial fails to rectify Sarepta’s sorry record
Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.
Mersana starts to lose its shine
The group’s latest data cut with XMT-1536 in ovarian cancer raises several red flags.
Atyr’s Covid-19 benefit claims raise questions
The group has blamed placebo “overperformance” on a high proportion of less-sick patients.
